Everads Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
3
Everads General Information
Description
Developer of retinal treatment therapy and technology designed to overcome significant technical challenges in effective suprachoroidal injection. The company's technology offers drug delivery and distribution, and offers potential long-term therapeutic effects, enabling patients to get improved compliance and outcomes.
Contact Information
Website
www.everads-therapy.comCorporate Office
- 27 Habarzel Street, Migdalei Orr
- Building A 5th Floor
- Tel Aviv 6971039
- Israel
Corporate Office
- 27 Habarzel Street, Migdalei Orr
- Building A 5th Floor
- Tel Aviv 6971039
- Israel
Everads Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
| 2. Grant | 29-Feb-2020 | Completed | Clinical Trials - Phase 1 | |||
| 1. Seed Round | 01-Jan-2017 | $950K | $950K | Completed | Clinical Trials - Phase 1 |
Everads Patents
Everads Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026053205-A1 | Means and method for suprachoroidal drug delivery to a back of an eye | Pending | 05-Sep-2024 | ||
| US-20240423832-A1 | Surgical fixation tool with coupling to injector/syringe | Pending | 31-Aug-2021 | ||
| WO-2023031723-A1 | Surgical fixation tool with coupling to injector/syringe | Inactive | 31-Aug-2021 | ||
| EP-4210644-A1 | Surgical fixation tool | Active | 08-Sep-2020 | ||
| EP-4210644-B1 | Surgical fixation tool | Active | 08-Sep-2020 | A61F9/007 |
Everads Signals
Everads Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Horizon 2020 | Government | |||
| RAD BioMed | Impact Investing | Minority | ||
| ARC Innovation Center | Accelerator/Incubator |
Everads Investments (1)
Everads’s most recent deal was a Joint Venture with Therapies for Retinal Diseases (Everads / VivaVision Biopharma). The deal was made on 06-Jan-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Therapies for Retinal Diseases (Everads / VivaVision Biopharma) | 06-Jan-2023 | Joint Venture | Drug Discovery |
Everads FAQs
-
When was Everads founded?
Everads was founded in 2017.
-
Where is Everads headquartered?
Everads is headquartered in Tel Aviv, Israel.
-
What is the size of Everads?
Everads has 9 total employees.
-
What industry is Everads in?
Everads’s primary industry is Drug Delivery.
-
Is Everads a private or public company?
Everads is a Private company.
-
What is Everads’s current revenue?
The current revenue for Everads is .
-
How much funding has Everads raised over time?
Everads has raised $950K.
-
Who are Everads’s investors?
Horizon 2020, RAD BioMed, and ARC Innovation Center have invested in Everads.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process